Alkermes says Caroline Loew to become CEO of Mural Oncology
Alkermes (NASDAQ:ALKS) has chosen Caroline Loew as CEO designate of Mural Oncology, the company said Thursday.
Mural Oncology is the new independent public company to be established upon the planned separation of the company's oncology business.
Loew will join Alkermes as a strategic advisor and transition to CEO of Mural Oncology upon completion of the separation, which remains on track to be completed in H2 of 2023.